Askari Pharmaceuticals

Gossamer Bio, originally founded as Askari Pharmaceuticals, is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company focuses on the discovery and development of novel therapeutics for immunology, inflammation, and oncology, with a primary emphasis on pulmonary vascular diseases. Its lead product candidate, seralutinib (GB002), is an inhaled small molecule tyrosine kinase inhibitor designed to target the PDGFR, CSF1R, and c-KIT pathways. Seralutinib is currently being evaluated in the Phase 3 PROSERA study for the treatment of pulmonary arterial hypertension (PAH). Gossamer Bio was established by the former leadership team of Receptos and is dedicated to improving patient outcomes through targeted kinase inhibition and GPCR biology. The company is publicly traded on the Nasdaq and maintains a strategic partnership with Chiesi Farmaceutici for the global development and commercialization of its lead program.